<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00190918</url>
  </required_header>
  <id_info>
    <org_study_id>8366</org_study_id>
    <secondary_id>H3E-US-JMGR</secondary_id>
    <nct_id>NCT00190918</nct_id>
  </id_info>
  <brief_title>A Trial for Patients With Gestational Trophoblastic Disease</brief_title>
  <official_title>A Phase II Trial of Pemetrexed (Alimta) in the Treatment of Recurrent or Persistent Low Risk Gestational Trophoblastic Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <brief_summary>
    <textblock>
      This phase II study is evaluating the activity of Pemetrexed in patients diagnosed with low
      risk Gestational Trophoblastic Tumor (GTT) that have failed prior treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the activity of Pemetrexed in failed low risk Gestational Trophoblastic Tumor (GTT) patients</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the toxicity of Pemetrexed in failed low risk Gestational Trophoblastic Tumor (GTT) patients</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Trophoblastic Neoplasms</condition>
  <condition>Uterine Neoplasms</condition>
  <condition>Hydatidiform Mole</condition>
  <condition>Choriocarcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persistent or recurrent low risk Gestational Trophoblastic Tumor (GTT)

          -  WHO score 2-6 (re-evaluated at the time of relapse

          -  Histologically confirmed complete or partial moles on initial evacuation

          -  Patients with mild to moderate renal insufficiency should avoid taking NSAIDs with
             short elimination half-lives for a period of 2 days before, the day of, and 2 days
             following administration of pemetrexed.

          -  All patients taking NSAIDs with longer half-lives, should interrupt dosing for at
             least 5 days before, the day of, and 2 days following pemetrexed administration.

          -  Folic Acid (350-1000 micrograms) must be given daily beginning approximately 5-7 days
             prior to first dose of pemetrexed and continuing daily until 3 weeks after the last
             dose of study therapy.

          -  Vitamin B12 (1000 micrograms) will be administered as an intramuscular injection
             approximately 1 to 2 weeks prior to first dose of pemetrexed and repeated
             approximately every 9 weeks until 3 weeks after the last dose of study therapy.

        Exclusion Criteria:

          -  Previous treatment that included chemotherapy other than actinomycin -D or
             methotrexate (+/- folinic acid).

          -  Patients with more than 8 metastatic lesions identified

          -  Patients with metastases to liver, spleen, brain, kidney or GI tract
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Miller, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gynecologic Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gynecologic Oncology Group 215-854-0770</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>August 7, 2007</last_update_submitted>
  <last_update_submitted_qc>August 7, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Choriocarcinoma</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
    <mesh_term>Hydatidiform Mole</mesh_term>
    <mesh_term>Gestational Trophoblastic Disease</mesh_term>
    <mesh_term>Trophoblastic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

